Jan 6, 2025 • 8:00 am EST Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Dec 9, 2024 • 7:00 am EST Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors
Dec 3, 2024 • 7:00 am EST FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
Nov 21, 2024 • 8:00 am EST Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference
Nov 12, 2024 • 8:00 am EST Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Nov 7, 2024 • 7:00 am EST Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update
Nov 4, 2024 • 7:00 am EST Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024
Oct 29, 2024 • 8:00 am EDT Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference
Oct 16, 2024 • 8:00 am EDT Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)
Sep 26, 2024 • 8:00 am EDT Corbus Pharmaceuticals to Participate in the BMO Capital Markets’ Oncology Summit